https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
zc:4789500609393632382
0
https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548
Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
zc:-7598314335784966354
0
https://www.zacks.com/stock/news/2228028/moderna-mrna-gears-up-for-q4-earnings-will-it-top-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228028
Feb 19, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
zc:-8195830911249071635
0
https://www.zacks.com/commentary/2228528/top-research-reports-for-merck-servicenow-blackstone?cid=CS-ZC-FT-research_daily-2228528
Feb 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX).
zc:-1483194522958927832
0
https://www.zacks.com/stock/news/2234897/merck-mrk-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2234897
Mar 01, 2024 - In the most recent trading session, Merck (MRK) closed at $126.96, indicating a -0.15% shift from the previous trading day.
zc:-1544955707279954085
0
https://www.zacks.com/commentary/2243512/top-research-reports-for-jpmorgan-chase-merck-sap?cid=CS-ZC-FT-research_daily-2243512
Mar 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).
zc:8659119032620171639
0
https://www.zacks.com/stock/news/2244951/merck-s-mrk-keytruda-lynparza-combo-fails-2nd-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244951
Mar 22, 2024 - Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
zc:5787282693942380442
0
https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062
Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
zc:-3776330917213329406
0
https://www.zacks.com/stock/news/2245870/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2245870
Mar 26, 2024 - Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
zc:-1848870639847693942
0
https://www.zacks.com/stock/news/2247337/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2247337
Mar 28, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zc:-4403643285499910555
0